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Abstract
Background—Identifying strong markers of prognosis is critical to optimize treatment and 
survival outcomes in patients with non-small cell lung cancer (NSCLC). We investigated the 
prognostic significance of preoperative cardiorespiratory fitness (VO2peak) among operable 
candidates with NSCLC.
Methods—Using a prospective design, 398 patients with potentially resectable NSCLC enrolled 
in Cancer and Leukemia Group B (CALGB) 9238 were recruited between 1993 and 1998. 
Participants performed a cardiopulmonary exercise test to assess VO2peak and were observed for 
death or until June 2008. Cox proportional models were used to estimate the risk of all-cause 
mortality according to cardiorespiratory fitness category defined by VO2peak tertiles (<0.96 / 0.96–
1.29 / >1.29 L.min−1) with adjustment for age, gender, performance status.
Results—Median follow-up was 30.8 months, 294 deaths were reported during this period. 
Compared with patients achieving a VO2peak <0.96 L.min−1, the adjusted hazard ratio (HR) for 
all-cause mortality was 0.64 (95% CI, 0.46 to 0.88) for a VO2peak of 0.96–1.29 L.min−1, and 0.56 
(95% CI, 0.39 to 0.80) for a VO2peak of >1.29 L.min−1 (ptrend= 0.0037). The corresponding HRs 
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for resected patients were 0.66 (95% CI, 0.46 to 0.95) and 0.59 (95% CI, 0.40 to 0.89) relative to 
the lowest VO2peak category (ptrend=0.0247), respectively. For non-resected patients, the HRs were 
0.78 (95% CI, 0.34 to 1.79) and 0.39 (95% CI, 0.16 to 0.94) relative to the lowest category 
(ptrend=0.0278).
Conclusions—VO2peak is a strong independent predictor of survival in NSCLC that may 
complement traditional markers of prognosis to improve risk stratification and prognostication.
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INTRODUCTION
Lung cancer is the second most commonly diagnosed malignancy among American adults 
accounting for approximately 15% of all cancer diagnoses.1 An estimated 80% of lung 
cancer patients will be diagnosed with non-small cell lung cancer (NSCLC) and ~25% will 
present with early-stage (operable) disease.1 NSCLC continues to be the leading cause of 
cancer-related mortality accounting for ~20% of all deaths.1 Despite significant 
advancements in surgical procedures and introduction of postoperative chemotherapy, 
prognosis remains disappointing with five-year relative survival rates ranging from ~70% for 
patients with stage I disease to only ~25% for stage IIIA disease.2 Further, there is 
considerable survival variability within stage due to the heterogeneous features of disease 
pathophysiology and broad range of clinical comorbid conditions at presentation.3, 4 Thus, 
identifying accurate markers of prognosis to optimize treatment and survival outcomes in 
NSCLC is of major clinical importance.
Among the wide spectrum of predictive and prognostic markers that have been identified, 
performance status (PS) has consistently been demonstrated to be a strong, independent 
predictor of survival and a central component of ‘practical’ prognostic models in NSCLC.3 
PS is an assessment of the patient’s physical functioning and capability of self-care as 
recorded by oncology health professionals but such scoring systems are subjective and have 
poor inter-rater reliability. Moreover, these instruments fail to characterize the degree or 
potential causes of physiologic limitation, assess symptom responses to exertion or inform 
therapeutic intervention.5
Cardiorespiratory fitness, as measured by an objective exercise tolerance test, reflects the 
integrative ability of the cardiopulmonary system to deliver adequate oxygen and substrate 
to metabolically active skeletal muscles for ATP resynthesis.6 Peak oxygen consumption 
(VO2peak) provides the gold standard (direct) assessment of cardiorespiratory fitness. Direct 
or estimated measurement of VO2peak is a well-established independent predictor of 
mortality in a broad range of non-cancer populations.7, 8 Accordingly, formalized exercise 
tolerance testing can provide powerful prognostic and risk stratification information to 
clinicians in these populations. In contrast, cardiorespiratory fitness assessment is not used 
in the oncology setting other than to provide a preoperative functional assessment of 
pulmonary resection candidates.5 Nevertheless, these tests may provide prognostic 
information beyond PS scoring systems currently used in the oncology setting. Here, we 
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investigate the prognostic significance of preoperative VO2peak on long-term all-cause 
mortality among operable candidates with NSCLC.
MATERIALS AND METHODS
Participants and Setting
Full details regarding the study sample, recruitment and procedures have been reported 
previously.9 In brief, study participants were enrolled in the Cancer and Leukemia Group B 
(CALGB) protocol 9238. CALGB protocol 9238 was a prospective, multi-institutional study 
to assess the utility of VO2peak for prediction of surgical risk including high risk patients 
with low FEV1. Patients with suspected stage I–IIIA lung cancer, with or without 
preoperative histological confirmation, who were candidates for primary surgery with 
curative intent were eligible for study participation. Additional eligibility requirements 
included adequate laboratory values (hemoglobin, PaO2, hematocrit, potassium) and 
estimated survival >2 years.9 Written informed consent was obtained from all participants 
prior to initiation of any study procedures.
Incremental Cardiopulmonary Exercise Testing
To determine VO2peak, an incremental, physician-supervised, cardiopulmonary exercise test 
(CPET) with 12-lead ECG monitoring was performed on an electronically-braked cycle 
ergometer with breath-by-breath expired gas analysis according to CPET guidelines for 
clinical populations.5, 10 All institutions used MedGraphics metabolic measurement systems 
with standardized electronic software. The exercise testing protocol was left to the discretion 
of the individual investigator. In general, however, preceding exercise, 3 minutes of resting 
metabolic data was collected before participants began cycling at 20W. Workloads were then 
increased 5–20W/min until volitional exhaustion or until a symptom-limitation was 
achieved.5 Workload increments were determined by the medical history of the participant 
and at the discretion of the individual investigator. During exercise oxyhemoglobin 
saturation was monitored continuously using pulse oximetry (BCI, Hand-Held Pulse 
Oximeter, Waukesha, WN) while blood pressure was measured non-invasively by manual 
auscultatory sphygmomanometry every two minutes. Patients continued with usual 
medications on the day of testing. All data was recorded as the highest 30s peak VO2 
elicited during the CPET. Mean percentage of age and sex-predicted VO2peak was calculated 
from the equations of Fitzgerald et al.11 and Wilson and Tanaka12.
Follow-up
Clinical endpoints were collected by the CALGB Statistical Center for at least 6 months 
post-surgery. Further follow-up survival data was obtained through the social-security death 
index.
Statistical Considerations
The Cox proportional hazards model was used to examine the impact of preoperative 
VO2peak on all-cause mortality. The effect of VO2peak (L.min−1 and mL.kg−1 min−1) was 
examined individually in these analyses with and without adjustment for the following 
covariables: age, gender, and performance status (0 vs. 1, 2). VO2peak was categorized into 
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three groups for L.min−1 (<0.96 L.min−1, 0.96–1.29 L.min−1 and >1.29 L.min−1) and 
mL.kg.−1min−1 (<13.9 mL.kg.−1min−1, 14.0–17.3 mL.kg.−1min−1, and >17.4 
mL.kg.−1min−1). These categories were determined post-hoc via an unbiased tertile split of 
distributions of all patients. The median value of VO2peak within each category was used as a 
predictor for linear trend in analyses. Survival time was defined as the time between 
registration and death; for patients remaining alive, survival was censored at the time of last 
known follow-up. Two sided p-values at the 0.05 level were used to determine statistical 
significance. All statistical analyses were performed using SAS Version 9.1.3 for Windows 
(SAS Institute, Cary, NC) by the CALGB statistical group. Graphics were performed using 
S-Plus version 8.0 for Windows.
RESULTS
Participant recruitment took place between August 1993 and July 1998. In brief, 422 
patients were registered during the study period. Of these, 398 (94%) are included in this 
ancillary analysis. Major reasons for exclusion are missing adequate medical or exercise 
testing data (n=24).
Participant Characteristics
The participant demographic and clinical characteristics are shown in Table 1. Mean age was 
64 ± 9 years, and 61% were male. For the total sample, 335 (84%) underwent surgical 
resection while 63 (16%) were deemed inappropriate for surgical resection at the 
determination of the attending thoracic surgeon. Thirteen patients died within 60 days of 
pulmonary resection. Overall, mean VO2peak was 1.18 ± 0.42 L.min−1 and 15.8 ± 0.43 
mL.kg−1 min−1; VO2peak (mL.kg−1 min−1) was, on average, 36% below that for age and sex-
matched normative data for sedentary individuals. FEV1, FEV1/FVC ratio, and DLCO was 
1.9 ± 0.8L (70% of predicted), 84 ± 18%, and 15.8 ± 6.0 mL.mm/Hg.min (73% of 
predicted), respectively.
Peak VO2 and All-Cause Mortality
Median follow-up was 30.8 months. During this period, 294 deaths were recorded (74% of 
the total sample). The median time from the cardiopulmonary exercise test to death was 3.7 
years (95% CI: 3.0 to 4.5) and 1.4 years (95% CI: 1.0 to 1.7) among surgical patients and 
non-surgical patients, respectively. For the entire sample, mortality rates declined across 
increasing absolute (L.min−1) and relative (mL.kg.−1min−1) VO2peak categories (adjusted 
Ptrend= 0.0037 and adjusted Ptrend= 0.08, respectively). Compared with patients achieving a 
VO2peak <0.96 L.min−1, the adjusted hazard ratio (HR) for all-cause mortality was 0.64 
(95% CI, 0.46 to 0.88) for a VO2peak of 0.96–1.29 L.min−1 and 0.56 (95% CI, 0.39 to 0.80) 
for a VO2peak of >1.29 L.min−1 (Table 2; Figure 1). The 5-year relative survival rate from 
the time of exercise testing was 28% for patients achieving a VO2peak <0.96 L.min−1 relative 
to 32% and 39% for patients achieving a VO2peak 0.96–1.29 L.min−1 and >1.29 L.min−1, 
respectively. Compared with a peak VO2 <13.9 mL.kg.−1min−1, (<3.9 METs) values of 
14.0–17.3 mL.kg.−1min−1 (4 METs to 4.9 METs) and >17.4 mL.kg.−1min−1 (>5.0 METs) 
were associated with a 21% and 24% reduction in the risk of all-cause mortality (Table 3; 
Figure 2).
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The corresponding HRs for resected patients are also shown in Tables 2 and 3. Compared 
with a peak VO2 <0.96 L.min−1, values of 0.96–1.29 L.min−1 and >1.29 L.min−1 were 
associated with a 34% and 41% reduction in the risk of all-cause mortality. The adjusted P 
for trend was 0.0247. The adjusted P for trend was non-significant (ptrend=0.39) for relative 
VO2peak (mL.kg.−1min−1) (Table 3). For non-resected patients, the HRs were 0.78 (95% CI, 
0.34 to 1.79) and 0.43 (95% CI, 0.16 to 0.94) relative to the lowest VO2peak (L.min−1) 
category (ptrend=0.02) (Table 2). The median length of survival from the time of exercise 
testing was 13.3 months for patients achieving a VO2peak <0.96 L.min−1 relative to 16.1 
months and 28.0 months for patients achieving a VO2peak 0.96–1.29 L.min−1 and >1.29 
L.min−1, respectively. The corresponding HRs for relative VO2peak (mL.kg.−1min−1) were 
0.34 (95% CI, 0.17 to 0.67) and 0.32 (95% CI, 0.14 to 0.71) relative to the lowest VO2peak 
category (ptrend=0.0015) (Table 3; Figure 3). Results of all analyses were unchanged after 
excluding the 13 patients who died of surgical complications within 60 days of exercise 
testing.
DISCUSSION
Our data demonstrate a strong and graded inverse association between VO2peak and all-cause 
mortality in patients with NSCLC. Compared with patients in the lowest VO2peak categories, 
higher VO2peak was associated with a statistically significant 21% to 24% reduction in the 
risk of mortality. These findings were consistent for age, gender, and performance status. 
The magnitude of risk reduction was even stronger for non-resected patients; in these 
patients, a VO2peak > 0.96 L.min−1 or 13.9 mL.kg.−1min−1 was associated with a 24% to 
61% reduction in the risk of mortality relative to the lowest VO2peak categories. Each 1.0 
mL.kg.−1min−1 increase in VO2peak was associated with a 4% reduction in all-cause 
mortality.
The magnitude of risk reduction in the current study is similar to the prognostic value of 
VO2peak in patients with ischemic heart disease and chronic heart failure. For example, 
Kavanagh et al.13 reported that compared with a VO2peak <13 mL.kg.−1min−1 values of ≥13 
mL.kg.−1min−1 were associated with a 50% and 29% reduction in the risk of cardiac 
mortality and all-cause mortality among >2,380 women referred for cardiac rehabilitation. 
Each 1.0 mL.kg.−1min−1 increase in VO2peak was associated with a 10% reduction in cardiac 
mortality. Similarly, Gitt et al.14 reported that a VO2peak <14 mL.kg.−1min−1 was associated 
with a 3-fold risk of death among 223 consecutive patients with heart failure. The strong 
prognostic value of VO2peak has been confirmed by several research groups.7, 8
The objective measurement of cardiorespiratory fitness using maximal (with direct or 
estimated assessment of VO2peak) or submaximal exercise testing for mortality prediction 
has not been exploited in the oncology setting. Several recent observational studies have 
provided the first evidence that self-reported physical activity (i.e., 9–18 MET-hrs.wk or ≥3–
6hrs.wk of moderate paced walking) is associated with a ~30% to ~50% reduction in cancer-
specific and all-cause mortality among early-stage breast and colorectal cancer patients.15, 16 
However, given the stark limitations of self-report assessment of physical activity exposure, 
there are several methods available to clinicians and investigators that enable the objective 
determination of cardiorespiratory fitness in the oncology setting. The method should be 
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determined by careful consideration of several factors including the purpose of the 
assessment (e.g., to determine exercise tolerance, prescribe exercise training, for 
cardiovascular diagnostics), the setting (e.g., hospital vs. community setting), and the cancer 
patient population (e.g., adjuvant vs. palliative care setting). These considerations have been 
reviewed in detail by our group elsewhere.5 In this study, we selected CPET because it 
provides the most accurate assessment of cardiorespiratory fitness and has been found to be 
a stronger predictor of prognosis than estimated methods of VO2peak.17 Despite the stark 
advantages of CPET, studies investigating the prognostic importance of submaximal testing 
(without gas exchange measurement) as well as functional capacity testing (e.g., six minute 
walk test) in lung and other solid malignancies are required. Such tests may be more 
appropriate in frail or elderly palliative patients, or when conducting a large number of tests 
in a non clinic-based setting. To this end, Kasymjanova et al.18 reported that six minute walk 
distance predicted prognosis in 45 patients with inoperable NSCLC.
The physiologic or molecular mechanisms underlying the association between VO2peak and 
mortality in NSCLC remain to be elucidated.19 In healthy populations, as well as those with 
CVD, the strong inverse relationship between cardiorespiratory fitness and CVD mortality is 
mediated by the association between high aerobic capacity (or exercise training-induced 
changes), established CVD risk factors, and possibly mitochondrial function.20 These 
pathways likely contribute, in part, to the graded mortality reduction observed in this study 
among resected patients as CVD is responsible for ~20%–30% of deaths in this group.3 In 
addition, high aerobic capacity and/or exercise-induced improvements in VO2peak may also 
impact cancer-specific mortality via direct and/or indirect mechanisms.3 For direct 
mechanisms, several postulated biologic pathways have been proposed to underlie the 
relationship between exercise and cancer progression including modulation of circulating 
metabolic and sex-steroid hormone concentrations, immune surveillance, and systemic 
inflammation / oxidative damage.21 These pathways are centrally intertwined with the 
cardinal features of solid tumor progression. In contrast, higher VO2peak and/or chronic 
aerobic training is postulated to be associated with lower circulating concentrations of 
metabolic and sex steroid hormones, enhanced immunity, and lower inflammation / 
oxidative injury.21 These effects are thought to act in concert to inhibit tumor progression 
although scant direct or correlative evidence currently exists to support this notion.22
‘Indirect’ factors such as muscle wasting (atrophy) may also play a role. In this study, low 
absolute VO2peak was strongly associated with a higher risk of mortality among resected 
patients whereas a weak association was observed for relative VO2peak (adjusted for body 
mass) suggesting that other factors associated with body composition and/or muscle 
structure / function may be important in determining prognosis in NSCLC. Measures of 
skeletal muscle function, cross-sectional area, and whole-body composition (lean vs. body 
mass) are powerful predictors of mortality in non-cancer chronic diseases23 (e.g., heart 
failure, pulmonary disease, and renal failure), as well as other cancer populations24–26 that, 
similar to NSCLC, experience a wasting syndrome. It is postulated that muscle and adipose 
tissue provide important energy reserves when exposed to a metabolic catabolic disease.27 
The prognostic value of body composition / skeletal muscle function, in addition to 
cardiorespiratory fitness, in NSCLC is warranted.
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Our findings may have implications for lung cancer mortality risk prediction and treatment. 
First, preoperative VO2peak is a well-established risk stratification tool to determine surgical 
complication risk28–31 and, on the basis on our findings, may have utility for long-term 
mortality prediction. VO2peak may provide an unbiased assessment of physical performance 
not permitted by current subjective PS scoring systems which may, in turn, provide more 
accurate prognostication and personalized care. To this end, our findings suggest that a 
VO2peak of <14 mL.kg.−1min−1 (determined from unbiased tertile data segregation) may 
identify patients with poor prognosis although confirmation is required. Other physiological 
objective measures, other than cardiorespiratory fitness testing, such as FEV1 may also be 
prognostic. In ancillary analyses, we found that mortality rates declined significantly across 
increasing absolute FEV1 (Ptrend= 0.0109) although FEV1 became non-significant with the 
addition of VO2peak in the multivariate model (analysis not presented). These preliminary 
results suggest that it is critically important to consider the integrative capacity of all organ 
components involved in O2 transport (as measured by VO2peak), as opposed to one 
component (such as lung function), when performing mortality risk prediction.
Second, our findings indicate that VO2peak may be an attractive therapeutic target to improve 
clinical outcome in NSCLC. Numerous reports have provided unequivocal evidence that 
aerobic training is associated with a 15% to 20% improvement in VO2peak32 in 12–15 weeks 
while changes in cardiorespiratory fitness are associated with substantial reductions in 
cardiovascular mortality irrespective of baseline fitness.33 Few studies have investigated the 
role of exercise training in NSCLC.34 Our group recently completed two pilot studies 
investigating the feasibility, safety, and preliminary efficacy of high-intensity supervised 
aerobic training on peak VO2peak among NSCLC patients in the preoperative (4–6 weeks of 
training)35 and postoperative (14 weeks of training)36 setting. VO2peak increased 2.4 
mL.kg.−1min−1 (14.6%) and 1.7 mL.kg.−1min−1 (11%) and preoperative and postoperative 
setting, respectively.35, 36 Based on the findings of this study, these improvements would 
potentially translate into a ~10% and ~7% improvement in overall survival. In comparison, 
adjuvant chemotherapy is associated with an absolute 5.3% improvement in survival over 5 
years.37 This preliminary data provide ‘proof of principle’ that a supervised aerobic training 
is safe and well-tolerated among operable NSCLC patients. On the basis of this data, our 
group is conducting an ongoing trial investigating the optimal type of exercise training to 
improve VO2peak in post-surgical NSCLC patients as well as change in the physiological 
mechanisms (i.e., organ components involved in O2 transport) that govern VO2peak.38
This study had several limitations. We only had information on death from any cause; the 
specific cause of death is not known. We also do not have information on disease recurrence 
and progression, disease stage or type and dose of any anticancer therapy (e.g., locoregional 
radiotherapy, chemotherapy, etc.), and the reasons for surgical ineligibility. Thus, analyses 
were not adjusted for these important covariates. Also patient selection bias may exist 
because of exclusion of patients deemed physically unable to perform exercise testing.
VO2peak is a strong independent predictor of survival in NSCLC that may complement 
traditional markers of prognosis to improve risk stratification and prognostication. Our 
findings further indicate that exercise training and/or other therapeutic strategies that 
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augment VO2peak may hold considerable promise for improving prognosis in patients with 
NSCLC.
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Kaplan-Meier survival curves for all-cause mortality by VO2peak (mL.kg.−1min−1) category 
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